M. Lagerlund

发表

Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy x 1) versus multiple fractions (3 Gy x 10) in the treatment of painful bone metastases.

P. Fayers, S. Kaasa, U. Falkmer, 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study

M. Fredrikson, E. Åvall-Lundqvist, M. Lagerlund, 2022, Breast Cancer Research and Treatment.

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.

L. Beckman, B. Zackrisson, P. Fransson, 2021, The Lancet. Oncology.

The quality assurance process for the ARTSCAN head and neck study - a practical interactive approach for QA in 3DCRT and IMRT.

T. Björk-Eriksson, F. Wiklund, S. Friesland, 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Ultrahypofractionation for prostate cancer : Outcome from the Scandinavian phase 3 HYPO-RT-PC trial

L. Beckman, P. Fransson, B. Johansson, 2018 .

Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey.

Vydmantas Atkocius, Peter Dunscombe, Yolande Lievens, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Clinical Oncology Module for the ESTRO Core Curriculum

I. Mjaaland, P. Lara, K. Benstead, 2021 .

Extreme hypofractionation: indications and results

L. Beckman, P. Nilsson, M. Lagerlund, 2016 .

Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: novel treatment predictive factors identified.

L. M. Bäcklund, O. Stål, H. Gréen, 2011, Cancer letters.

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial

L. Beckman, B. Zackrisson, P. Fransson, 2019, The Lancet.

Extreme Hypofractionation versus Conventionally Fractionated Radiotherapy for Intermediate Risk Prostate Cancer : Early Toxicity Results from the Scandinavian Randomized Phase III Trial "HYPO-RT-PC"

L. Beckman, P. Fransson, P. Nilsson, 2016 .

Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).

D. Amadori, S. Fosså, A. Haese*, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

D. Amadori, S. Fosså, C. Parker, 2011 .

Clinical outcome following radiotherapy and planned neck dissection in N+ head and neck cancer patients

S. Friesland, M. Lagerlund, F. Lewin, 2008, Acta oto-laryngologica.